Navigation Links
Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
Date:9/24/2009

CAMBRIDGE, Mass., Sept. 24 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

After more than 70 years of work a safe and effective dengue virus (DENV) vaccine remains an elusive goal. Previous vaccine candidates have shown unpredictable interactions among the four DENVs often leading to unwanted reactogenicity and low seroconversion rates. Rapid, serotype-specific diagnosis of DENV infection is an equally perplexing problem. Existing tests are often confounded after secondary dengue infection due to extensive serotype cross-reactivity, and the rapid evolution of DENV strains in many regions of the world.

Peptimmune has developed a novel peptide copolymer-based technology, DEEP (Directed Expansion of Epitope Permutations), which may overcome these problems. The goal of this research and development collaboration is to evaluate the DEEP technology to potentially design DENV-specific peptide copolymers containing (1) potentially protective T-cell epitopes, (2) serotype-specific diagnostic epitopes, and (3) protective B-cell epitopes for generating immuno-prophylactic antibodies. WRAIR/NMRC investigators bring to the effort their expert knowledge of DENV. Evaluation of the diagnostics and vaccines generated in the collaboration will be performed in laboratory models at WRAIR/NMRC.

The results of this collaborative effort have the potential to provide important insights into dengue immunity and advance the development of a protective vaccine.

About DEEP

DEEP is a peptide copolymer technology that is able to target the hypervariable regions of viruses generating antigenic diversity to anticipate evolutionary changes and overcome immune-dominance, while preserving antigenic specificity by incorporating any desired B- or T-cell epitope. DEEP takes advantage of Peptimmune's know-how in the solid-phase manufacturing of complex peptide mixtures. The technology combines the epitope specificity of a fixed-sequence peptide with the randomness of a broadly immune-interactive copolymer.

About Peptimmune (www.peptimmune.com)

Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptides and peptide mixtures for use as novel vaccines, ligands for antibodies, and theranostics for autoimmune disorders.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
2. Peptimmune Presentations at Upcoming Events
3. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
4. Peptimmune Announces First Close of Series D Private Financing
5. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
6. Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community
7. Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology
8. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
9. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
10. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
11. DuPont and Arzeda Collaborate to Develop Improved Crops to Increase Productivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... The medical potential of stem cells is both extensive and ... due to their differentiating characteristics. Stem cells are unique as the have the potential ... to become tissue or organic-specific cells with special functions. , Stem cell therapy ...
(Date:2/21/2017)... ... February 21, 2017 , ... VetStem Biopharma, ... its headquarters laboratory in Poway, California. Based upon 12 years of knowledge ... personnel and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
(Date:2/21/2017)... YORK , Feb. 21, 2017   Logicalis ... an international IT solutions and managed services provider ( ... – Service Desk for Epic. The new service will ... internal Epic resources by giving physicians, nurses and other ... specialists for tier-one support. This will allow hospital IT ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
Breaking Biology News(10 mins):